Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible to participate in the study if all of the following criteria are met:~1. Males and female subjects 18 years of age and older.~2. Subjects with locally advanced unresectable adenocarcinoma (cytological or histologic proof required) of the pancreas.. Patients with islet cell tumors are not eligible.~3. No clinical evidence of distant metastases, excluding single liver metastasis and local lymph node involvement. Patients with more than a single liver metastasis and/or other metastases who have already failed systemic chemotherapy and/or are on a break from systemic chemotherapy who are not surgical candidates can also qualify for this study.~4. Karnofsky Performance Status (KPS) \>60.~5. Adequate renal, and bone marrow function described as:~   1. Leukocytes ≥ 3,000/uL~  2. Absolute neutrophil count ≥ 1,500/uL~  3. Platelets ≥100,000/uL~  4. Serum creatinine ≥2.0 mg/dL. Creatinine less than or equal to 1.5 mg/dL or creatinine clearance greater than 40 mL/min/1.73 m2 for patients with creatinine levels above institutional normal, as calculated by the Cockcroft Gault formula.~  5. Hemoglobin ≥8.5 g/dL (may be receiving supportive therapy)~  6. PT/PTT (WNL)~6. Adequate Hepatic function (endoscopic or percutaneous drainage as needed) described as:~   1. Total bilirubin ≤3 times UNL (less than or equal to 2 mg/dL)~  2. AST (SGOT)/ALT (SGPT) ≤ 5 times ULN or ≤5 times ULN in the setting of liver metastases.~  3. Lipase and Amylase within normal limits.~7. Capable of understanding the purpose and risks of the study and willing to provide written informed consent and to comply with the procedures~Exclusion Criteria:~Subjects will be excluded from participation in the study if any of the following criteria are met:~1. Have a known sensitivity to gemcitabine.~2. Identification of metastatic disease, with the exception of single liver metastases or local lymph node involvement. Patients with more than a single liver metastasis and/or other metastases who have already failed systemic chemotherapy and/or are on a break from systemic chemotherapy who are not surgical candidates can also qualify for this study.~3. Evidence of coagulopathy.~4. Inability or unwillingness to comply with study procedures and/or follow-up procedures.~5. Evidence of infection or other coexisting medical condition, which in the opinion of the investigator would preclude administration of gemcitabine.~6. Patients with uncontrolled congestive heart failure, unstable angina and myocardial infarction within 3 months.~7. Female patient who is pregnant, nursing or planning on becoming pregnant.~8. Current enrollment and participation in another clinical study or prior exposure to an investigational agent within 12 weeks or 5 half-lives (whichever is longer) of anticipated dosing on Day 1 of this study.~9. Have known brain metastases.~10. Have had any major surgery within four weeks of enrollment.~11. Have any clinically detectable ascites.~12. Have uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.~13. Have serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.~14. Other invasive malignancies within the past 3 years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or prostate cancer) not approved by the Medical Monitor (contact MM in event of prior diagnosis with malignancy to discuss enrollment status).~15. Have had any chemotherapy or systemic corticosteroids within 2 weeks of study entry.~16. Have acquired, hereditary or congenital immunodeficiency's including cellular immunodeficiencies, hypogammaglobulinemia and dysgammaglobulinemia or hepatitis.~17. Have a prior history of a documented hemolytic event.~18. Is HIV-positive or Hepatitis positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine, Local Delivery (Dose 1) (Type: OTHER): Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
- Gemcitabine, Local Delivery (Dose 2) (Type: OTHER): Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
- Gemcitabine, Local Delivery (Dose 3) (Type: OTHER): Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
- Gemcitabine, Local Delivery (Dose 4) (Type: OTHER): Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete